Sofosbuvir/ledipasvir raises some antiretroviral levels in HIV/HCV coinfected people

HIV/HCV coinfected people who take sofosbuvir/ledipasvir (Harvoni) to treat hepatitis C along with boosted protease inhibitor antiretroviral regimens may experience changes in drugs levels, but these are mostly not considered clinically relevant, according to a drug-drug interaction study presented at the 2015 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. However, data on the safety and efficacy of combining sofosbuvir/ledipasvir with boosted protease inhibitors during treatment are lacking, and increased tenofovir exposure may be a concern.

The advent of interferon-free direct-acting antiviral regimens has brought about a revolution in treatment for chronic hepatitis C virus (HCV) infection, including for patients who have traditionally been considered 'difficult to treat', such as those with HIV/HCV coinfection. Clinical trials have seen cure rates for coinfected people equal to those for patients with HCV alone, and current treatment guidelines and product labels indicate that HIV-positive patients can be treated with the same recommended regimens as HIV-negative ones, taking into account potential interactions with antiretroviral therapy (ART).

Polina German of Gilead Sciences reported findings from a phase 1 study to evaluate interactions between sofosbuvir/ledipasvir and ART regimens containing ritonavir-boosted atazanavir (Reyataz) or darunavir (Prezista) plus tenofovir/emtricitabine (Truvada) in healthy HIV-negative volunteers.


Labels: , ,